Linapil 5mg Tablet contains Linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated for the management of type 2 diabetes mellitus. Linagliptin works by enhancing the levels of incretin hormones, which increase insulin secretion and decrease glucagon release in a glucose-dependent manner, thereby improving glycemic control. This medication is prescribed as an adjunct to diet and exercise to improve blood sugar levels in adults with type 2 diabetes. Linapil 5mg is particularly beneficial for patients who require additional glycemic control without the risk of hypoglycemia commonly associated with some other antidiabetic agents. It is administered orally once daily, with or without food. Linagliptin is primarily excreted via the enterohepatic system, making dose adjustment unnecessary in patients with renal impairment. Common adverse effects may include nasopharyngitis, headache, and upper respiratory tract infections, though it is generally well tolerated. Linapil should be used cautiously in patients with a history of pancreatitis. It is contraindicated in individuals with type 1 diabetes or diabetic ketoacidosis. Regular monitoring of blood glucose and HbA1c levels is recommended to assess therapeutic efficacy and guide treatment adjustments.